Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
21 February, 2018 14:15 IST
Jubilant Life' arm to negotiate potential acquisition of speciality biz in USA
Source: IRIS | 21 Mar, 2017, 10.16AM
Comments  |  Post Comment

Jubilant Life Sciences' material wholly owned subsidiary in Singapore, Jubilant Pharma (JPL) has received an approval to negotiate a potential acquisition of a speciality pharma business in the United States using only internal accruals, subject to due diligence, satisfactory agreements, etc. and its final approval. The board of directors of JPL at its meeting has approved for the same.

The proposed acquisition is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL's existing business, if it materializes.

Shares of the company gained Rs 7.65, or 0.97%, to trade at Rs 793.00. The total volume of shares traded was 81,616 at the BSE (10.08 a.m., Tuesday).



Jubilant Life Sciences Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
SSWL wins exports order from German OEM-BMW - 21-Feb-2018 12:15
BHEL bags Rs 10.34 bn captive power plant order - 21-Feb-2018 12:07
Reliance Ind to acquire 5% stake in Eros Int'l PLC - 21-Feb-2018 10:51
IRB Infra Developers receives appointed date for Kishangarh Gulabpura Tollway project - 21-Feb-2018 09:44
USFDA completes pre-approval inspection at Biocon Malyasia - 21-Feb-2018 09:31
CMI Energy bags order from Engineers India - 20-Feb-2018 14:27
Suven Life Sciences secures product patents in India and South Korea - 20-Feb-2018 10:47
IndusInd Bank intimates of no direct credit exposure to Nirav Modi - 20-Feb-2018 09:58
JSW Energy enters into MoU with Govt of Maharashtra - 20-Feb-2018 09:53
Subex partners with Pod Solution - 20-Feb-2018 09:49
Glenmark Pharma presents findings from Phase 2a study of GBR 830 - 19-Feb-2018 10:10
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer